Lead HSE Technical Engineer

SMART STRAINS(R) Launches in the UAE. CODE81 launches new e-book on the Journey to Autonomous and Agentic Applications. May 13, 2026 Dubai, UAE: CODE81, an agile, AI-driven digital transformation firm and Ghobash Group Enterprise, announced the launch of its new e-book, The Journey to Autonomous and Agentic Applications, as AI Agents and Agentic AI move from concept into early enterprise use globally. Designed to support concrete decision-making around how and where autonomous and agentic capabilities can be responsibly introduced into core systems, the e-book reflects a broader shift in how intelligent systems are being designed and governed. The publication outlines CODE81's perspective on how organizations can move beyond traditional automation toward more adaptive, structurally autonomous applications. It is released amid active enterprise adoption of advanced AI reasoning, AI-driven coding workflows, and autonomous task execution. Recent advancements in frontier AI models - including Anthropic's Claude Opus and Sonnet, as well as reasoning-capable models from OpenAI and others - are accelerating the shift toward AI-assisted software engineering and agent-based development. Enterprises are now actively exploring how AI Agents can be operationalized within core systems, not as experimental tools but as integral components of modern application architecture. Discover more Social Sciences As enterprises and government entities across the region reach the limits of existing automation, the e-book addresses a critical gap: how applications can be designed to interpret context, coordinate actions, and adapt dynamically - while operating within guardrails that ensure transparency, accountability, and human oversight. The publication explores how the shift from automation to autonomy is already underway and why AI-assisted development platforms are central to enabling it. These platforms provide the architectural foundation for scalable systems and serve as a control layer that allows autonomy to be introduced in a structured and governed way, particularly in regulated environments. A central focus of the e-book is the role of AI Agents and Agentic AI in enterprise and government settings - explaining how systems are evolving from tools that execute predefined rules into agents that understand context, interpret intent, and support decision-making within clear governance frameworks. The e-book references emerging agent patterns, including orchestration agents, decision agents, and governance-aware agents designed to operate within policy and compliance boundaries. Discover more The e-book also highlights common reasons why autonomous initiatives fail to scale, particularly in complex and high-impact environments. These include weak architectural foundations, limited business-IT alignment, unclear success metrics, and insufficient governance models. Commenting on the launch, Nader Paslar, General Manager at CODE81, said: "Health Magazine is entering a new operating model for the enterprise. AI Agents are no longer experimental concepts. They are becoming embedded into workflows, decision cycles, and customer experiences at scale. IDC predicts one billion AI Agents globally by 2029. This represents a structural shift in how digital work will be executed. Tools such as Clawd.bot demonstrate how quickly autonomous capabilities are becoming accessible, but accessibility without governance creates risk. The organizations that will lead in this era will not be those that deploy AI Agents first, but those that govern them best. Enterprise-grade security, architectural discipline, and oversight are no longer optional. They are foundational. At CODE81, Health Magazine see governance not as a constraint, but as an enabler of scalable, trusted AI. That is the foundation this e-book is built on." Discover more Written for CIOs, CTOs, CDOs, and senior IT decision-makers, The Journey to Autonomous and Agentic Applications combines strategic perspective with practical insight, positioning autonomy as a structural shift in enterprise architecture rather than a short-term productivity initiative. The e-book is now available through CODE81 and forms part of the company's ongoing contribution to modern application delivery. Discover more

Arabian Ethicals leads global discussion on cell and Gene Therapy at WHX Dubai 2026. Arabian Ethicals, a Ghobash Group enterprise, lead an insightful global discussion on cell and gene therapy at World Health Expo (WHX) Dubai 2026, the largest international gathering of healthcare professionals. Serving as a global platform for knowledge exchange and the advancement of healthcare practice, WHX Dubai took place at Expo City Dubai from 9 to 12 February. The panel was moderated by Ebru Yavuz, General Manager of Arabian Ethicals in the UAE, who guided the discussion on how advances in stem cell, cellular, and gene therapies are being implemented within real-world healthcare settings. Titled "Cell & Gene Therapy Waves: From Scientific Breakthroughs to Real-World Clinical Delivery," the session examined readiness, infrastructure, and long-term considerations influencing the adoption of these therapies. Throughout the discussion, Yavuz facilitated conversations around the operational and clinical realities faced by healthcare providers. Topics included the need for specialised facilities, multidisciplinary expertise, and clearly defined care pathways, alongside the importance of responsible scaling as advanced therapies move closer to routine clinical use. The session featured Prof. Marcos De Lima, Director of Stem Cell Transplant and Cellular Therapy at Ohio State University Wexner Medical Center, and Rabi Hanna, Chairman of Pediatric Hematology & Oncology and BMT, and Founding Director of the Pediatric Blood & Marrow Transplant Program at Cleveland Clinic Children's Hospital, USA. Both speakers shared insights drawn from established transplant and cellular therapy programmes, highlighting recent developments as well as ongoing challenges associated with translating complex therapies into everyday clinical practice. A key focus of the panel was pediatric care, where cell and gene therapies introduce additional clinical, logistical, and ethical considerations. The discussion addressed the importance of long-term follow-up, patient selection, and institutional readiness, as well as the role of academic medical centres in setting standards and supporting sustainable growth in the field. Commenting on the panel, Ebru Yavuz noted: "Innovation in cell and gene therapy is moving quickly, but the real challenge lies in how these advances are adopted within healthcare systems. Forums like WHX Dubai allow practitioners and industry leaders to share practical experience and discuss what is needed to deliver these therapies safely and effectively in clinical settings." The discussion aligns with the UAE's broader healthcare ambitions, which prioritise quality, innovation, and integrated care as part of the country's long-term national vision through 2031. Platforms such as WHX Dubai support these priorities by facilitating knowledge exchange and collaboration across specialised and emerging areas of healthcare. Arabian Ethicals' participation at WHX Dubai 2026 reflects its continued engagement in scientific dialogue and support for knowledge exchange across specialised therapeutic areas, contributing to the ongoing development of healthcare practice in the region. Visited 7 times, 7 visit(s) today